NAMPT and hepatocellular carcinoma: Upregulation of the NAD+ salvage pathway, particularly via nicotinamide phosphoribosyltransferase (NAMPT), sustains HCC survival, and its inhibition by agents like FK866 depletes NAD+ pools, inducing mitochondrial dysfunction and ROS accumulation to sensitize tumors to sorafenib or cisplatin [72,73,74].